From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Galiximab (IDEC 114) is a primatized immunoglobulin G1 (IgG1) lambda monoclonal antibody directed against the CD80 antigen and blocks CD80–CD28 binding. Galiximab has variable regions are primatized (cynomologous monkeys), and the constant regions are human. Galiximab can be used in research of B-cell lymphoma .
PD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 TFA interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC50s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 TFA can be used for the research of various diseases, including cancer and infectious diseases .
Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody . Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively .
Durvalumab (anti-PD-L1)(MEDI 4736) is a human anti-PD-L1 protein monoclonal antibody. Durvalumab (anti-PD-L1) completely blocks PD-L1 binding to PD-1 and CD80, IC 50 are 0.1 and 0.04 nM respectively, has anti-tumor activity .
CD80 Human Pre-designed siRNA Set A contains three designed siRNAs for CD80 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Davoceticept (ALPN-202; CD80 vIgD-Fc) is a monoclonal antibody targeting CTLA-4. Davoceticept consists of the (1-107) fragment of CD80 linked to IGHG1 Fc via a peptidyl linker. The expression system of Davoceticept is usually CHO (Chinese Hamster Ovary) cells .
PD-1/PD-L1-IN 3, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC50s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 can be used for the research of various diseases, including cancer and infectious diseases .
HSP90-IN-31 (compound Be01) causes reduction of CD80 and CD86 expression on dendritic cells (DCs). HSP90-IN-31 decreases the production of pro-inflammatory cytokines (IL-6, TNF-α, and IL-1β) in BMDC and peritoneal macrophages stimulated by LPS (HY-D1056). Under the delayed-type hypersensitivity (DTH) mice model, HSP90-IN-31 reduces ear swelling and pro-inflammatory cytokines in the spleen .
ODN D-SL03 is a C class CpG oligonucleotides, can induce stimulate PBMCs to produce high level of IFN-α. ODN D-SL03 can activate human B cells, NK cells and mononuclear cells and up-regulate expression of CD80, CD86 and HLA-DR on the surface of subsets in human PBMCs. ODN D-SL03 also can inhibit the growth of the tumor. ODN D-SL03 sequence: 5'-tcgcgaacgttcgccgcgttcgaacgcgg-3' .
ODN D-SL03 sodium is a C class CpG oligonucleotides, and can induce stimulate PBMCs to produce high level of IFN-α. ODN D-SL03 sodium can activate human B cells, NK cells and mononuclear cells and up-regulate expression of CD80, CD86 and HLA-DR on the surface of subsets in human PBMCs. ODN D-SL03 sodium also can inhibit the growth of the tumor. ODN D-SL03 sequence: 5'-tcgcgaacgttcgccgcgttcgaacgcgg-3' .
Belatacept (BMS 224818) is a selective T-cell costimulation blocker. Belatacept binds to CD 80/86 ligands and thereby inhibits the CD-28-mediated T-cell costimulation. Belatacept can be used in the research of Immunosuppression in organ transplants .
ORN 06 (Compound R-0006), a U-rich single-stranded RNA (containing 6 repeats of the UUG sequence motif), is a TLR7/8 agonist. ORN 06 stimulates human TLR7/8-mediated or murine TLR7-mediated immunity .
PD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 TFA interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC50s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 TFA can be used for the research of various diseases, including cancer and infectious diseases .
Galiximab (IDEC 114) is a primatized immunoglobulin G1 (IgG1) lambda monoclonal antibody directed against the CD80 antigen and blocks CD80–CD28 binding. Galiximab has variable regions are primatized (cynomologous monkeys), and the constant regions are human. Galiximab can be used in research of B-cell lymphoma .
Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody . Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively .
Durvalumab (anti-PD-L1)(MEDI 4736) is a human anti-PD-L1 protein monoclonal antibody. Durvalumab (anti-PD-L1) completely blocks PD-L1 binding to PD-1 and CD80, IC 50 are 0.1 and 0.04 nM respectively, has anti-tumor activity .
Davoceticept (ALPN-202; CD80 vIgD-Fc) is a monoclonal antibody targeting CTLA-4. Davoceticept consists of the (1-107) fragment of CD80 linked to IGHG1 Fc via a peptidyl linker. The expression system of Davoceticept is usually CHO (Chinese Hamster Ovary) cells .
Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody . Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively .
B7-1/CD80 Protein, Mouse (HEK293, His) is not only expressed on APCs, but also is expressed on T cells. B7-1:PD-L1 interaction can inhibit T cell proliferation and cytokine production.
B7-1/CD80 Protein, Rat (HEK293, His) is not only expressed on APCs, but also is expressed on T cells. B7-1:PD-L1 interaction can inhibit T cell proliferation and cytokine production.
CD80 is a costimulatory cytokine for cancer immunity that is activated by binding to CD28 or CTLA-4. Tumor immune evasion occurs when CD80 expression is low. The increased expression of CD80 induced by TP53 stimulates anti-tumor immune responses. B7-1/CD80 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived B7-1/CD80 protein, expressed by HEK293 , with C-6*His labeled tag.
The CD80 protein plays a key role in T lymphocyte activation, promoting proliferation and cytokine production through CD28 binding. In contrast, interaction with CTLA-4 inhibits T cell activation. B7-1/CD80 Protein, Human (HEK293, His) is the recombinant human-derived B7-1/CD80 protein, expressed by HEK293 , with C-6*His labeled tag.
B7-1/CD80 Protein is pivotal in providing the costimulatory signal crucial for T lymphocyte activation. T-cell proliferation and cytokine production hinge on the binding of CD28 or CTLA-4 to this receptor. As a crucial immune response mediator, B7-1/CD80 facilitates dynamic interplay between T cells and regulatory receptors, influencing essential processes for T lymphocyte activation and regulation in the immune system. B7-1/CD80 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived B7-1/CD80 protein, expressed by HEK293 , with C-His labeled tag.
CD80 is a costimulatory cytokine for cancer immunity that is activated by binding to CD28 or CTLA-4. Tumor immune evasion occurs when CD80 expression is low. The increased expression of CD80 induced by TP53 stimulates anti-tumor immune responses. B7-1/CD80 Protein, Cynomolgus (HEK293, Fc) is the recombinant cynomolgus-derived B7-1/CD80 protein, expressed by HEK293 , with C-hFc labeled tag.
B7-1/CD80 Protein is pivotal in providing the costimulatory signal crucial for T lymphocyte activation. T-cell proliferation and cytokine production hinge on the binding of CD28 or CTLA-4 to this receptor. As a crucial immune response mediator, B7-1/CD80 facilitates dynamic interplay between T cells and regulatory receptors, influencing essential processes for T lymphocyte activation and regulation in the immune system. B7-1/CD80 Protein, Rabbit (HEK293, His) is the recombinant Rabbit-derived B7-1/CD80 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of B7-1/CD80 Protein, Rabbit (HEK293, His) is 209 a.a., with molecular weight of 30-50 kDa.
B7-1/CD80 Protein, crucial in activating T lymphocytes, engages CD28 or CTLA-4 receptors, inducing proliferation and cytokine production. This interaction regulates immune responses and influences T lymphocyte activation and function. Serving as a key checkpoint, B7-1/CD80 orchestrates signaling events, controlling the immune system's dynamic responses. B7-1/CD80 Protein, Mouse (Biotinylated, HEK293, His) is the recombinant mouse-derived B7-1/CD80 protein, expressed by HEK293 , with C-His labeled tag.
B7-1/CD80, a type I membrane protein, is a member of the B7 family, with an extracellular immunoglobulin constant-like domain and a variable-like domain required for receptor binding.CD80 is also a transmembrane glycoprotein and a member of the Ig superfamily.CD80 has a crucial role in modulating T-cell immune function as a checkpoint protein at the immunological synapse.Its binding to CD28 or CTLA-4 receptors is integral to inducing T-cell proliferation and cytokine production.B7-1/CD80 Protein, Rat (HEK293, Fc) is the recombinant rat-derived B7-1/CD80 protein, expressed by HEK293 , with C-hFc labeled tag.
B7-1/CD80 Protein is pivotal in providing the costimulatory signal crucial for T lymphocyte activation. T-cell proliferation and cytokine production hinge on the binding of CD28 or CTLA-4 to this receptor. As a crucial immune response mediator, B7-1/CD80 facilitates dynamic interplay between T cells and regulatory receptors, influencing essential processes for T lymphocyte activation and regulation in the immune system. B7-1/CD80 Protein, Cynomolgus (HEK293, hFc) is the recombinant cynomolgus-derived B7-1/CD80 protein, expressed by HEK293 , with C-hFc labeled tag.
The CD80 protein plays a key role in T lymphocyte activation, promoting proliferation and cytokine production through CD28 binding. In contrast, interaction with CTLA-4 inhibits T cell activation. B7-1/CD80 Protein, Human (HEK293, His-Avi) is the recombinant human-derived B7-1/CD80 protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of B7-1/CD80 Protein, Human (HEK293, His-Avi) is 208 a.a., with molecular weight of 50-70 kDa.
The CD80 protein plays a key role in T lymphocyte activation, promoting proliferation and cytokine production through CD28 binding. In contrast, interaction with CTLA-4 inhibits T cell activation. B7-1/CD80 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived B7-1/CD80 protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of B7-1/CD80 Protein, Human (Biotinylated, HEK293, His-Avi) is 208 a.a., with molecular weight of 50-70 kDa.
B7-1/CD80 Protein, Mouse (HEK293, Fc) is not only expressed on APCs, but also is expressed on T cells. B7-1:PD-L1 interaction can inhibit T cell proliferation and cytokine production.
B7-1/CD80 Protein, Human (HEK293, Fc) is a polypeptide chain with the C-termimal human IgG1 Fc fragment produced in HEK293 cells. CD80 is a costimulatory molecule known for its role in T-cell activation and also in regulating normal and malignant B cellsactivity.
CD80 Antibody is an unconjugated, approximately 30 kDa, mouse-derived, anti-CD80 monoclonal antibody. CD80 Antibody can be used for: WB, IHC-P,FC ICC expriments in mouse,human, and predicted: rat background without labeling.
B7-1 Antibody (YA1413) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1413), targeting B7-1. B7-1 Antibody (YA1413) can be used for FC, ELISA experiment in human background.
ODN D-SL03 sodium is a C class CpG oligonucleotides, and can induce stimulate PBMCs to produce high level of IFN-α. ODN D-SL03 sodium can activate human B cells, NK cells and mononuclear cells and up-regulate expression of CD80, CD86 and HLA-DR on the surface of subsets in human PBMCs. ODN D-SL03 sodium also can inhibit the growth of the tumor. ODN D-SL03 sequence: 5'-tcgcgaacgttcgccgcgttcgaacgcgg-3' .
CD80 Human Pre-designed siRNA Set A contains three designed siRNAs for CD80 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
ODN D-SL03 is a C class CpG oligonucleotides, can induce stimulate PBMCs to produce high level of IFN-α. ODN D-SL03 can activate human B cells, NK cells and mononuclear cells and up-regulate expression of CD80, CD86 and HLA-DR on the surface of subsets in human PBMCs. ODN D-SL03 also can inhibit the growth of the tumor. ODN D-SL03 sequence: 5'-tcgcgaacgttcgccgcgttcgaacgcgg-3' .
Inquiry Online
Your information is safe with us. * Required Fields.
